Viewing StudyNCT04670913



Ignite Creation Date: 2024-05-06 @ 3:34 PM
Last Modification Date: 2024-10-26 @ 1:51 PM
Study NCT ID: NCT04670913
Status: UNKNOWN
Last Update Posted: 2021-06-29
First Post: 2020-11-26

Brief Title: Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy
Sponsor: Junling Li
Organization: Peking Union Medical College

Conditions & Keywords Data

Conditions:
Name
Advanced Non Squamous NSCLC
Keywords:
Name View
First-Line Immunotherapy View
programmed cell death 1 PD-1 PD1 View
programmed cell death-ligand 1 PD-L1 PDL1 View
anti-angiogenesis View